Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2013, specifically dated September 12, 2013. The filing serves to announce a corporate development regarding the Company's securities trading status in the United States.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a regulatory approval and does not contain financial statements or performance data.
Material Changes
On September 12, 2013, the Company received approval for its Level II American Depositary Receipt (ADR) program. This approval allows the Company's securities to trade on the U.S. Over-the-Counter Markets under the ticker symbol "CANFY".
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or a discussion of risks and contingencies. The document solely incorporates a press release regarding the ADR program approval.
Investor Verification Checklist
- Verify the trading status of the ticker symbol "CANFY" on U.S. Over-the-Counter Markets.
- Confirm the details of the Level II ADR program structure.
- Review the attached press release (Exhibit 99.1) for any additional context not summarized in the filing body.